Dupixent — Medica

Initial criteria

• age ≥ 12 years
• urticaria for > 6 weeks with symptoms present > 3 days per week despite daily non-sedating H1 antihistamine therapy titrated up to 4 times the standard FDA-approved dose
• prescribed by or in consultation with allergist, immunologist, or dermatologist

Reauthorization criteria

• already received ≥ 6 months of Dupixent therapy
• experienced beneficial clinical response (decreased itch severity OR decreased number or size of hives)

Approval duration

initial 6 months, renewal 1 year